Literature DB >> 18472231

GC-MS confirmation of xylazine (Rompun), a veterinary sedative, in exchanged needles.

Nayra Rodríguez1, José Vargas Vidot, Juan Panelli, Héctor Colón, Bob Ritchie, Yasuhiro Yamamura.   

Abstract

In order to assess the extent of xylazine (Xyz) injection in Puerto Rico, two waves of used-syringe collections were performed. In the first, syringes were gathered, anonymously and without additional information; in the second, a short interview, also anonymous, was administered. We found Xyz in 37.6% of the collected syringes; the majority of the Xyz-containing syringes came from ranching communities. Syringes containing Xyz more frequently also contained "speedball" than those without (90.6% and 66.7%, respectively). Self-reports of Xyz injection deviated markedly from actual detection: only 50% (self-described users) and 22% (self-described non-users) of the collected syringes contained the drug. With a high prevalence of skin ulcers (38.5% vs. 6.8%; p<0.001), Xyz users were more likely to be in poor health compared to non-users. Surprisingly, though a higher percentage of Xyz users than non-users had college-level educations (23.1% vs. 5.5%), they were more likely to be homeless (64.1% vs. 37%).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18472231      PMCID: PMC2527692          DOI: 10.1016/j.drugalcdep.2008.03.005

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  22 in total

1.  An unusual presentation from xylazine-ketamine.

Authors:  F Ozlem Arican; Taha Okan; Ozer Badak; Sema Guneri
Journal:  Vet Hum Toxicol       Date:  2004-12

2.  An exploratory qualitative study of polydrug use histories among recently initiated injection drug users in San Juan, Puerto Rico.

Authors:  H Ann Finlinson; Héctor M Colón; Rafaela R Robles; Mayra Soto-López
Journal:  Subst Use Misuse       Date:  2006       Impact factor: 2.164

3.  A comparative study of mortality among Puerto Rican injection drug users in East Harlem, New York, and Bayamon, Puerto Rico.

Authors:  Hector Manuel Colon; Sherry Deren; Rafaela Rivera Robles; Sung-Yeon Kang; Myrna Cabassa; Hardeo Sahai
Journal:  J Urban Health       Date:  2006-11       Impact factor: 3.671

4.  Ketamine abusers presenting to the emergency department: a case series.

Authors:  A L Weiner; L Vieira; C A McKay; M J Bayer
Journal:  J Emerg Med       Date:  2000-05       Impact factor: 1.484

Review 5.  Xylazine toxicity--literature review and report of two cases.

Authors:  R E Mittleman; W L Hearn; G W Hime
Journal:  J Forensic Sci       Date:  1998-03       Impact factor: 1.832

Review 6.  Severe intoxication with the veterinary tranquilizer xylazine in humans.

Authors:  U Hoffmann; C M Meister; K Golle; M Zschiesche
Journal:  J Anal Toxicol       Date:  2001 May-Jun       Impact factor: 3.367

7.  Canadian veterinarians' use of analgesics in cattle, pigs, and horses in 2004 and 2005.

Authors:  Caroline J Hewson; Ian R Dohoo; Kip A Lemke; Herman W Barkema
Journal:  Can Vet J       Date:  2007-02       Impact factor: 1.008

8.  Drug abuse with inhalated xylazine.

Authors:  Jose I Elejalde; Clint Jean Louis; Rosario Elcuaz; Miguel A Pinillos
Journal:  Eur J Emerg Med       Date:  2003-09       Impact factor: 2.799

9.  Patterns of use and harms associated with non-medical ketamine use.

Authors:  Paul Dillon; Jan Copeland; Karl Jansen
Journal:  Drug Alcohol Depend       Date:  2003-01-24       Impact factor: 4.492

10.  Human overdose with the veterinary tranquilizer xylazine.

Authors:  D G Spoerke; A H Hall; M J Grimes; B N Honea; B H Rumack
Journal:  Am J Emerg Med       Date:  1986-05       Impact factor: 2.469

View more
  9 in total

1.  Xylazine (veterinary sedative) use in Puerto Rico.

Authors:  Rafael A Torruella
Journal:  Subst Abuse Treat Prev Policy       Date:  2011-04-11

2.  The emerging of xylazine as a new drug of abuse and its health consequences among drug users in Puerto Rico.

Authors:  J C Reyes; J L Negrón; H M Colón; A M Padilla; M Y Millán; T D Matos; R R Robles
Journal:  J Urban Health       Date:  2012-06       Impact factor: 3.671

3.  The validity of drug use responses in a household survey in Puerto Rico: comparison of survey responses with urinalysis.

Authors:  H M Colón; C M Pérez; M Meléndez; E Marrero; A P Ortiz; E Suárez
Journal:  Addict Behav       Date:  2010-02-10       Impact factor: 3.913

4.  Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis.

Authors:  Joseph Friedman; Fernando Montero; Phillippe Bourgois; Rafik Wahbi; Daniel Dye; David Goodman-Meza; Chelsea Shover
Journal:  Drug Alcohol Depend       Date:  2022-02-26       Impact factor: 4.852

5.  Addressing the HIV/AIDS epidemic among Puerto Rican people who inject drugs: the need for a multiregion approach.

Authors:  Sherry Deren; Camila Gelpí-Acosta; Carmen E Albizu-García; Ángel González; Don C Des Jarlais; Salvador Santiago-Negrón
Journal:  Am J Public Health       Date:  2014-09-11       Impact factor: 9.308

6.  Toxic effects of xylazine on endothelial cells in combination with cocaine and 6-monoacetylmorphine.

Authors:  L A Silva-Torres; C Vélez; J Lyvia Alvarez; J G Ortiz; B Zayas
Journal:  Toxicol In Vitro       Date:  2014-07-08       Impact factor: 3.500

7.  Xylazine as a drug of abuse and its effects on the generation of reactive species and DNA damage on human umbilical vein endothelial cells.

Authors:  Luz Silva-Torres; Christian Veléz; Lyvia Alvarez; Beatriz Zayas
Journal:  J Toxicol       Date:  2014-11-11

8.  Xylazine-Induced Skin Ulcers in a Person Who Injects Drugs in Philadelphia, Pennsylvania, USA.

Authors:  Srikrishna V Malayala; Bhavani Nagendra Papudesi; Raymond Bobb; Aliya Wimbush
Journal:  Cureus       Date:  2022-08-19

9.  Xylazine-induced reduction of tissue sensitivity to insulin leads to acute hyperglycemia in diabetic and normoglycemic monkeys.

Authors:  Yong-Fu Xiao; Bingdi Wang; Xiaoli Wang; Fenglai Du; Michael Benzinou; Yi-Xin Jim Wang
Journal:  BMC Anesthesiol       Date:  2013-10-20       Impact factor: 2.217

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.